Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

I understand the suicides reported with psoriasis treatments were likely unrelated, but I am concerned about liability using it?

Psoriasis

Unfortunately, with what happened with the bridaliumab data and some of the other issues with biologics translated to the overall treatment of psoriasis, that has basically mandated covering the issues of suicide, depression, anxiety and all the other components. I think in the end, I would go over those with the patients, would ask them how are they doing with their regular life, but also how much of their depression, anxiety and other issues are related to psoriasis. And I would break through some of the components of that to get into, okay, let's look under the hood. Let's talk about what's really going on, because again, these assays and these reportings are very sterile. They look at did you have a research event? Did you have a flare? Did you have this and that? They're all very sterile in terms of taking to the patient count or the encounter. So that's up to us, I think, as physicians as well as investigators in the trial to really get under the hood and say, all right, what's going on with you? Is there an issue? Anything I need to worry about? And more so is anything you need to worry about and anything you're undergoing that would be a problem with not only keeping in the trial, but also are you going to be able to maintain therapies? So a lot of that is based on the nature of treatment. I mean, are they able to sustain, are they able to go forward with the psoriasis treatments? And even more so, are they understanding the risk benefits, alternatives, where they're going? So that's really what we're looking for.